ArticleScientific reports2019
Combining hippocampal volume metrics to better understand Alzheimer's disease progression in at-risk individuals.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- High-resolution MRI evidence for age- and sex-related changes in hippocampal subfield volume during healthy aging.GeroScience · 2026Article
- Integration of glymphatic system function and hippocampal radiomics for diagnosis and conversion prediction of Alzheimer's disease.BMC medical imaging · 2026Article
- Age-Associated Cortical Thinning in Speech Motor Regions Precedes Hippocampal Decline: Implications for Alzheimer's Disease.Human brain mapping · 2025Article
- Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting.Journal of neurology · 2024Article
- Enhanced hippocampal TIAM2S expression alleviates cognitive deficits in Alzheimer's disease model mice.Pharmacological reports : PR · 2024Article
- Article
- Cardiorespiratory fitness, hippocampal subfield morphology, and episodic memory in older adults.Frontiers in aging neuroscience · 2024Article
- Clinically feasible automated MRI volumetry of the brain as a prognostic marker in subjective and mild cognitive impairment.Frontiers in neurology · 2024Article
- Detection and treatment of Alzheimer's disease in its preclinical stage.Nature aging · 2023Review
- Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging.Brain and behavior · 2023Review
- The Molecular Effects of Environmental Enrichment on Alzheimer's Disease.Molecular neurobiology · 2022Review
- Prediction of Chronological Age in Healthy Elderly Subjects with Machine Learning from MRI Brain Segmentation and Cortical Parcellation.Brain sciences · 2022Article
- Diagnosis of early mild cognitive impairment using a multiobjective optimization algorithm based on T1-MRI data.Scientific reports · 2022Article
- Breakdown of the blood-brain barrier: A mediator of increased Alzheimer's risk in patients with metabolic disorders?Journal of neuroendocrinology · 2022Review
- Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study.Journal of Alzheimer's disease : JAD · 2021Article
- Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.Current research in pharmacology and drug discovery · 2021Review
- Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2020Article
- Mechanical property alterations across the cerebral cortex due to Alzheimer's disease.Brain communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
To date nearly all clinical trials of Alzheimer's disease (AD) therapies have failed. These failures are, at least in part, attributable to poor endpoint choice and to inadequate recruitment criteria. Recently, focus has shifted to targeting at-risk populations in the preclinical stages of AD thus improved predictive markers for identifying individuals likely to progress to AD are crucial to help inform the sample of individuals to be recruited into clinical trials. We focus on hippocampal volume (HV) and assess the added benefit of combining HV and rate of hippocampal atrophy over time in relation to disease progression. Following the cross-validation of previously published estimates of the predictive value of HV, we consider a series of combinations of HV metrics and show that a combination of HV and rate of hippocampal atrophy characterises disease progression better than either measure individually. Furthermore, we demonstrate that the risk of disease progression associated with HV metrics does not differ significantly between clinical states. HV and rate of hippocampal atrophy should therefore be used in tandem when describing AD progression in at-risk individuals. Analyses also suggest that the effects of HV metrics are constant across the continuum of the early stages of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.